Myriad Genetics (MYGN) Tops Q4 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. META
4. NFLX
5. TSLA
6. ISRG
7. SMCI
8. GOOGL
9. RTX
10. USO

Go back to Myriad Genetics (MYGN) Tops Q4 EPS by 4c

Myriad Genetics Reports Fiscal Fourth-Quarter 2017 and Fiscal Full-Year 2017 Financial Results

August 8, 2017 4:06 PM EDT

Total Revenues of $200.5 Million Up 8 PercentGAAP Diluted EPS was $0.19 and Adjusted EPS of $0.30Record Hereditary Cancer Demand and 86 Percent of Revenue Under Long-Term ContractCompany Issues Fiscal Year 2018 and Fiscal First-Quarter 2018 Financial Guidance

SALT LAKE CITY, Aug. 08, 2017 (GLOBE NEWSWIRE) --  Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and personalized medicine, today announced financial results for its fiscal fourth-quarter 2017 and fiscal full-year 2017, provided an update on recent business highlights and issued its fiscal year 2018 and fiscal first-quarter... More